一、院校简介

利物浦大学（University of Liverpool）是一所研究型大学，位于英格兰西北部港口城市利物浦市。学校是著名的罗素大学集团（The Russell Group）和N8研究合作集团的成员之一。利物浦大学成立于1881年，是英国六所最原始的“红砖大学”之一。学校在多个研究领域享有极高的国际声誉，迄今为止学校校友及学术人员中共有10位诺贝尔奖得主（包括英国的第一位诺贝尔奖得主）并孕育出了英国第一位普利兹克建筑奖得主。

利物浦大学是英国第一所建立建筑学、城市设计、生物化学、海洋学的大学，拥有英国国家海洋研究中心、约翰斯顿实验室等前沿机构。利物浦大学在医药学、建筑 、城市规划、环境学、理学、工程、计算机科学、法学、MBA以及兽医科学等领域的教学研究名声卓越。

利物浦大学位列2024QS世界大学排名第176位。

二、招聘职位

01药理学博士

申请人在利物浦的研究生学习通常需要持有英国一级或二级以上学位分类的第一学位，或二级学位加硕士学位。同等的国际资格也是可以接受的，它们的同等性将根据国家学术认可和信息中心(NARIC)提供的信息以及内部指导进行评估，内部指导基于我们对资格作为我们课程准备的适用性的经验。

研究兴趣

-药物安全科学不良反应是患者、医疗保健系统和制药行业的一个重大问题。为表彰其在药物安全科学领域的卓越成就，MRC授予该部门一笔中心赠款。MRC药物安全科学中心是欧洲唯一的同类中心。我们对药物不良反应的原因、特征和后果进行临床和基础研究，并侧重于药物不良反应的机制和遗传易感性。我们的任务是改善这些反应的诊断和临床处理。

-个性化医疗-个性化医疗有能力彻底改变英国及其他国家治疗严重疾病的方式。该部门在沃尔夫森个性化医学中心工作，其研究重点是识别与心血管疾病、哮喘和癫痫等临床领域相关的药物反应的预测性遗传标记。

-临床和基础科学家致力于检测能够决定患者对药物反应的基因和途径。我们研究的最终目的是将实验室发现转化为临床护理，为患者和医疗保健系统造福。感染和炎症——我们致力于了解已获许可的药物和新的纳米技术药物的药代动力学和动力学之间的关系。我们的研究影响了那些最需要它的人，从实验室到临床，再到在人群中的应用。该系配备了最先进的设施，包括分子和细胞生物学套件和生物分析平台。这使我们能够通过使用证据综合、临床前和临床评估来定义传染病的关键机制过程，从而真正弥合实验室和现实世界之间的差距。我们因在艾滋病毒和丙型肝炎方面的研究而闻名。

-神经药理学——涵盖从基础到临床的所有领域，我们在三个关键领域开展工作:癫痫、疼痛、精神健康和行为。我们正在领导世界上一些最大的临床试验，我们的项目解决了治疗学中一些最重要的问题。我们正在评估免疫调节药物在不明原因的慢性疼痛疾病中的应用。最后，我们使用分子遗传学和生物化学，结合临床、心理和精神病学数据来研究CNS功能障碍。

02神经科学博士

学生通常需要在相关的生物科学学科中获得至少2:1的荣誉学位，或同等的医学、兽医或牙科资格。申请人的选择是基于他们的简历、资格和推荐人的报告，以及他们成功完成课程的能力，以及所提供的培训对他们随后的职业规划的价值。

01Pharmacology PhD

Applicants for postgraduate research study at Liverpool are normally expected to hold a UK first degree with a First Class or Upper Second Class degree classification, or a Second Class degree plus a Master’s degree. Equivalent international qualifications are also accepted, and their equivalence will be evaluated on the basis of the information provided by the National Academic Recognition and Information Centre (NARIC) as well as internal guidance based on our experience of a qualification’s suitability as a preparation for our programmes.

Research interests

-Drug Safety Science Adverse reactions are a significant problem for patients, healthcare systems and the pharmaceutical industry. Recognizing its excellence in the field of drug safety science, the MRC awarded the department a Centre grant. The MRC Centre for Drug Safety Science is the only Centre of its kind in Europe. We carry out clinical and basic research into the causes, characteristics and consequences of adverse drug reactions and focus on the mechanisms and genetic predisposition of adverse reactions to drugs. Our mission is to improve diagnosis and clinical handling of these reactions.

-Personalised Medicine – Personalized medicine has the power to revolutionize the way in which serious diseases are treated in the UK and beyond. Working from the Wolfson Centre for Personalised Medicine, the Departments research focuses on identifying predictive genetic markers for drug responses associated with clinical areas including cardiovascular disease, asthma and epilepsy. -Clinical and basic scientists are dedicated to detecting genes and pathways that can determine a patient’s response to a drug. The ultimate aim of our research is to translate laboratory findings into clinical care for the benefit of patients and healthcare systems. 

Infection and Inflammation – We are committed to understanding the relationship between pharmacokinetics and dynamics for both licensed medicines and new nanotechnology-enabled medicines. Our research impacts on those people who need it most, extending from the laboratory to the clinic through to application at the population level. The Department is equipped with state-of-the-art facilities, including molecular and cell biology suites and bioanalytical platforms. These allow us to define the key mechanistic processes of infectious diseases by using evidence synthesis, pre-clinical and clinical evaluations, and therefore truly bridge the gap between the lab and the real world. We are renowned for our research in HIV and Hepatitis C. 

-Neuropharmacology – Covering everything from basic to clinical we work across three key areas: epilepsy, pain and mental health and behavior. We are leading some of the largest clinical trials in the world and our programme addresses some of the most significant issues in therapeutics. We are evaluating the use of immunomodulatory drugs for unexplained chronic pain conditions. Finally, we use molecular genetics and biochemistry, integrated with clinical, psychological and psychiatric data to investigate CNS dysfunction.

02Neurological Science PhD

Students will normally have a minimum of a 2:1 class honours degree in a relevant biological science subject, or an equivalent medical, veterinary or dental qualification. Applicants are selected on the basis of their curriculum vitae, qualifications and referees’ reports, together with their perceived ability to complete the programme successfully and on the value of the training offered to their subsequent career plans.

三、语言要求

英语语言要求

雅思学术要求-SELT和非SELT：总分6.5分，不低于5.5分

托福网考要求：最低总分88分，包括L 17 W 17 R 17和S 19

C1高级CAE要求：总分176分，任何一篇论文不低于162分

伦敦三一学院，英语综合技能(ISE II)：ISE II，总分及格，部分成绩优异

剑桥IGCSE作为第一语言：C级

剑桥IGCSE作为第二语言：B级

ESOL国际剑桥英语三级证书(熟练程度)：总分176分，分项162分

ESOL国际剑桥英语三级证书(高级)：总分176分，分项162分

ESOL国际剑桥英语二级证书(高级)：总分176分，分项162分

English language requirements

IELTS Academic requirement-SELT and non-SELT：Overall 6.5 no band below 5.5

TOEFL iBT requirement：Minimum 88 overall with L 17 W 17 R 17 and S 19

C1 Advanced CAE requirement：Overall 176 with no less than 162 in any paper

Trinity College London, Integrated Skills in English (ISE II)：ISE II with an overall pass with merit in components

Cambridge IGCSE as a First Language：Grade C

Cambridge IGCSE as a Second Language：Grade B

Cambridge English Level 3 Certificate in ESOL International (Proficiency)：Overall 176 with 162 in components

Cambridge English Level 3 Certificate in ESOL International (Advanced)：Overall 176 with 162 in components

Cambridge English Level 2 Certificate in ESOL International (Advanced)：Overall 176 with 162 in components

四、申请方式

申请全年开放。

Applications are open all year round.

Email：info@zhengzicn.com